Xmrk, Kras and Myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zheng, Weiling ^a   Li, Zhen ^a   Nguyen, Anh Tuan ^a   Li, Caixia ^a   Emelyanov, Alexander ^b   Gong, Zhiyuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MYC PROTEIN; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENETIC IDENTIFICATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE XMRK; RNA SEQUENCE; TRANSCRIPTOMICS; TRANSGENIC ANIMAL; UPREGULATION; ZEBRA FISH; ANIMAL; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; ONCOGENE RAS; PHYSIOLOGY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR PROTEIN-TYROSINE KINASES; ZEBRAFISH;

EID: 84898473157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091179     Document Type: Article

References (50)

1. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, et al. (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62-67. (Pubitemid 29023987)
2. Siegel AB, Olsen SK, Magun A, Brown RS Jr (2010) Sorafenib: where do we go from here? Hepatology 52: 360-369.
3. Leenders MW, Nijkamp MW, Borel Rinkes IH (2008) Mouse models in liver cancer research: a review of current literature. World J Gastroenterol 14: 6915-6923.
4. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, et al. (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311. (Pubitemid 39577940)
5. Liu S, Leach SD (2011) Zebrafish models for cancer. Annu Rev Pathol 6: 71-93.
6. Li Z, Zheng W, Wang Z, Zeng Z, Zhan H, et al. (2012) An inducible Myc zebrafish liver tumor model revealed conserved Myc signatures with mammalian liver tumors. Dis Model Mech.
7. Nguyen AT, Emelyanov A, Koh CH, Spitsbergen JM, Parinov S, et al. (2012) An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. Dis Model Mech 5: 63-72.
8. Nguyen AT, Emelyanov A, Koh CH, Spitsbergen JM, Lam SH, et al. (2011) A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech 4: 801-813.
9. Li Z, Huang X, Zhan H, Zeng Z, Li C, et al. (2011) Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. J Hepatol 56: 419-425.
10. Lu JW, Hsia Y, Tu HC, Hsiao YC, Yang WY, et al. (2011) Liver development and cancer formation in zebrafish. Birth Defects Res C Embryo Today 93: 157-172.
11. Liu W, Chen JR, Hsu CH, Li YH, Chen YM, et al. (2012) A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology 56: 2268-2276.
12. Amatruda JF, Shepard JL, Stern HM, Zon LI (2002) Zebrafish as a cancer model system. Cancer Cell 1: 229-231. (Pubitemid 41039146)
13. Spitsbergen JM, Tsai HW, Reddy A, Miller T, Arbogast D, et al. (2000) Neoplasia in zebrafish (Danio rerio) treated with 7,12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. Toxicol Pathol 28: 705-715.
14. Mirbahai L, Williams TD, Zhan H, Gong Z, Chipman JK (2011) Comprehensive profiling of zebrafish hepatic proximal promoter CpG island methylation and its modification during chemical carcinogenesis. BMC Genomics 12: 3.
15. Lam SH, Gong Z (2006) Modeling liver cancer using zebrafish: a comparative oncogenomics approach. Cell Cycle 5: 573-577.
16. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, et al. (2006) Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 24: 73-75. (Pubitemid 43083168)
17. Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531. (Pubitemid 351881844)
18. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, et al. (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128.
19. Gomez A, Wellbrock C, Gutbrod H, Dimitrijevic N, Schartl M (2001) Ligandin-dependent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. J Biol Chem 276: 3333-3340.
20. Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, et al. (2007) COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol 14: 752-758. (Pubitemid 46175323)
21. Gan FY, Gesell MS, Alousi M, Luk GD (1993) Analysis of ODC and c-myc gene expression in hepatocellular carcinoma by in situ hybridization and immunohistochemistry. J Histochem Cytochem 41: 1185-1196. (Pubitemid 23220226)
22. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, et al. (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55. (Pubitemid 40070939)
23. Zheng W, Wang Z, Collins JE, Andrews RM, Stemple D, et al. (2011) Comparative transcriptome analyses indicate molecular homology of zebrafish swimbladder and mammalian lung. PLoS One 6: e24019.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. (Pubitemid 41528093)
25. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, et al. (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-947. (Pubitemid 46646500)
26. Lee JS, Grisham JW, Thorgeirsson SS (2005) Comparative functional genomics for identifying models of human cancer. Carcinogenesis 26: 1013-1020. (Pubitemid 41214294)
27. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
28. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
29. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378. (Pubitemid 36184095)
30. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 microarray software suite. Methods Enzymol 411: 134-193.
31. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788-8793.
32. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, et al. (2012) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142: 957-966 e912
33. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, et al. (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212.
34. Liu X, Wang X, Zhang J, Lam EK, Shin VY, et al. (2010) Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29: 442-450.
35. Chen M, Zhang J, Li N, Qian Z, Zhu M, et al. (2011) Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 6: e25564.
36. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, et al. (2011) MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 71: 2286-2297.
37. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, et al. (2004) Treatment of HCC with pravastatin, octreotide, or gemcitabine-a critical evaluation. Hepatogastroenterology 51: 1099-1103. (Pubitemid 38822478)
38. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, et al. (2008) Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78: 34-38.
39. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, et al. (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891. (Pubitemid 32385829)
40. Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, et al. (2009) Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res 15: 1808-1813.
41. Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, et al. (2007) N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer 6: 32.
42. Hsieh SY, Huang SF, Yu MC, Yeh TS, Chen TC, et al. (2010) Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49: 476-487.
43. Gan L, Guo K, Li Y, Kang X, Sun L, et al. (2010) Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep 23: 1037-1043.
44. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, et al. (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558.
45. Wang X, Chen Y, Han QB, Chan CY, Wang H, et al. (2009) Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 9: 242-253.
46. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, et al. (2005) CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24: 367-380. (Pubitemid 40188585)
47. Li Y, Wan D, Wei W, Su J, Cao J, et al. (2008) Candidate genes responsible for human hepatocellular carcinoma identified from differentially expressed genes in hepatocarcinogenesis of the tree shrew (Tupaia belangeri chinesis). Hepatol Res 38: 85-95. (Pubitemid 350182580)
48. Mavaddat N, Dunning AM, Ponder BA, Easton DF, Pharoah PD (2009) Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev 18: 255-259.
49. Meplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, et al. (2010) Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 31: 1074-1079.
50. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, et al. (2011) Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 107: 126-134.